Improvement of long-term preservation of the isolated arrested rat heart by trimetazidine: Effects on the energy state and mitochondrial function

Kay, Laurence; Finelli, Caterina; Aussedat, J.; Guarnieri, Carlo; Rossi, André

doi:10.1016/0002-9149(95)90064-0

Cited by 20 publications

(14 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Many in-vitro and animal experiments have found cardioprotective effects of TMZ on different parameters of cell metabolism via its antioxidant properties and its causing a reduction in cellular acidosis (Demaison et al 1995;Kay et al 1995;Di Pasquale et al 1999;Kantor et al 2000;Cross et al 2000;El Banani et al 2000;Rogacka et al 2000;Szwed et al 2001a). When given before cardiologic interventions, TMZ has been found to improve ventricular function without altering hemodynamics, limit infarct area, and reduce both platelet aggregation and leukocyte migration to the area (Fabiani et al 1992;Steg et al 2001).…”

Section: Discussionmentioning

confidence: 99%

“…During ischemic episodes, TMZ maintains cellular ATP levels, limits intracellular acidosis and accumulation of inorganic phosphate, Na + and Ca ++ in cardiac tissue. These changes are independent of oxygen supply or demand alterations (Demaison et al 1995;Kay et al 1995;Cross 2000;Kantor et al 2000). Trimetazidine selec-tively inhibits the fatty acid β -oxidation enzyme: 3 ketoacyl-CoA-thiolase, and lacks direct hemodynamic effects (Stanley and Marzilli 2003;Tabbi-Anneni et al 2003;Stanley 2004;Folmes et al 2005;Grynberg 2005).…”

confidence: 99%

See 1 more Smart Citation

Suppression of Angioplasty-Related Inflammation by Pre-Procedural Treatment with Trimetazidine

Kuralay

Altekin

Yazlar

et al. 2006

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

Percutaneous transluminal coronary angioplasty (PTCA) has been recognized as a reliable treatment procedure for acute reversible ischemia and reperfusion. Ischemic reperfusion cycle in PTCA leads to the systemic inflammation and extensive tissue injury by the production of reactive oxygen species including nitric oxide (NO) radicals. In patients with coronary artery disease, undergoing PTCA, the effects of trimetazidine (TMZ), a piperazine-derivative anti-anginal drug, were studied on several indirect markers of systemic inflammatory response: tumor necrosis factor-α (TNF-α ), C-reactive protein (CRP) and NO products (nitrite and nitrate). Patients (n = 11 each group) were untreated or pre-treated with TMZ (20 mg per orally three times a day), begun three days prior to PTCA, and marker levels were measured before the start of TMZ therapy (baseline), just before PTCA (0 hr), and 4, 24, and 48 hrs after PTCA. The baseline levels of markers were not significantly different between the untreated and pre-treated patients. In contrast, all parameters were lower in the TMZtreated group than those in the matched control group in the pre-and post-angioplasty periods. Interestingly, in the TMZ group, CRP and nitrite levels were significantly lower than in the control group at each time point of the pre-and post-angioplasty periods, but the TNF-α levels were significantly decreased only in the post-angioplasty period. Preprocedural treatment with oral TMZ for three days significantly suppressed the elevation of inflammatory markers before and shortly after PTCA. We suggest the usefulness of TMZ in preventing inflammatory cardiovascular events after PTCA.trimetazidine; percutaneous transluminal coronary angioplasty; C-reactive protein; nitric oxide; tumor necrosis factor-α .

show abstract

Section: Discussionmentioning

confidence: 99%

Suppression of Angioplasty-Related Inflammation by Pre-Procedural Treatment with Trimetazidine

Kuralay

Altekin

Yazlar

et al. 2006

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

show abstract

“…Trimetazidine (TMZ) is an effective and well-tolerated anti-ischemic agent which has a cytoprotective action during ischemia [1][2][3]. TMZ is frequently prescribed as a prophylactic treatment of episodes of angina pectoris [4] and as a symptomatic treatment of vertigo and tinnitus [5,6].…”

Section: Introductionmentioning

confidence: 99%

Protective Effect of Trimetazidine in a Model of Ischemia-Reperfusion in the Rat Retina

Mohand‐Saïd¹,

Jacquet²,

Lucien³

et al. 2002

Ophthalmic Res

View full text Add to dashboard Cite

Trimetazidine is an anti-ischemic agent which is frequently prescribed as a prophylactic treatment of episodes of angina pectoris and as a symptomatic treatment of vertigo and tinnitus. It has also shown beneficial effects in models of visual dysfunction, but the mechanism(s) by which this occurs is as yet undefined. The present study was intended to evaluate the influence of trimetazidine on retinal damage induced by ischemia-reperfusion in a rat model. Retinal ischemia was induced by increasing intraocular pressure to 160 mm Hg for 60 min. Trimetazidine or buffer controls were administered 3 days before the ischemia or in the postischemic period. The degree of retinal damage was assessed after 15 and 30 days of reperfusion after the ischemic insult by histopathologic study according to Hughes’ quantification of ischemic damage. Retinal ischemia led to significant reductions in thickness and cell number, mainly in the inner retinal layers. The results from the study demonstrate that treatment with intraperitoneally injected trimetazidine conferred significant protection against retinal ischemic damage. Better results were obtained in the pretreatment group after 15 days of reperfusion. Trimetazidine protects the rat retina from pressure-induced ischemic injury and might be considered a potential therapeutic modality for combating retinal ischemia.

show abstract

“…The proposed mechanism is direct enhancement of myocardial energy metabolism, resulting in cytoprotective effects (Harpey, 1989;Kay et al, 1995). Fantini et al showed that in isolated rat heart mitochondria, trimetazidine has an inhibitory effect on palmitoylcarnitine oxidation, with no significant effect on pyruvate oxidation (Fantini et al, 1994).…”

Section: Pharmacological Effectsmentioning

confidence: 99%

Therapy for Angina Pectoris Secondary to Coronary Disease

Innasimuthu¹,

Kumar²,

Gao³

et al. 2011

Angina Pectoris

View full text Add to dashboard Cite

Improvement of long-term preservation of the isolated arrested rat heart by trimetazidine: Effects on the energy state and mitochondrial function

Cited by 20 publications

References 5 publications

Suppression of Angioplasty-Related Inflammation by Pre-Procedural Treatment with Trimetazidine

Suppression of Angioplasty-Related Inflammation by Pre-Procedural Treatment with Trimetazidine

Protective Effect of Trimetazidine in a Model of Ischemia-Reperfusion in the Rat Retina

Therapy for Angina Pectoris Secondary to Coronary Disease

Contact Info

Product

Resources

About